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SUMMARY
Autism spectrum disorder (ASD) and intellectual
disability (ID) are often comorbid, but the extent to
which they share common genetic causes remains
controversial. Here, we present two autosomal-
recessive ‘‘founder’’ mutations in the CC2D1A
gene causing fully penetrant cognitive phenotypes,
including mild-to-severe ID, ASD, as well as sei-
zures, suggesting shared developmental mecha-
nisms. CC2D1A regulates multiple intracellular
signaling pathways, and we found its strongest
effect to be on the transcription factor nuclear fac-
tor kB (NF-kB). Cc2d1a gain and loss of function
both increase activation of NF-kB, revealing a crit-
ical role of Cc2d1a in homeostatic control of intra-
cellular signaling. Cc2d1a knockdown in neurons
reduces dendritic complexity and increases NF-kB
activity, and the effects of Cc2d1a depletion can
be rescued by inhibiting NF-kB activity. Homeo-
static regulation of neuronal signaling pathways
provides a mechanism whereby common founder
mutations could manifest diverse symptoms in
different patients.
INTRODUCTION
Autism spectrum disorder (ASD) is a highly heritable neuropsy-
chiatric condition, but its genetic architecture remains unclear.
Although common genetic variants have been shown to confer
risk for this disorder (Cross-Disorder Group of the Psychiatric
Genomics Consortium et al., 2013), ASD is also caused by rare
mutations of large effect, suggesting a genetic architecture
partially similar to intellectual disability (ID) (Devlin and Scherer,
2012). Because ASD is comorbid with ID in 30%–50% of cases
(Developmental Disabilities Monitoring Network Surveillance
Year 2010 Principal Investigators, 2014), these disorders may
not be genetically distinct. However, it is not clear howmutations
in the same gene can have divergent consequences, ranging
from severe ID to prominent social defects with preserved intel-
lectual function.
Here, we report that null mutations in coiled-coil and C2
domain containing 1A (CC2D1A) consistently cause a variable
spectrum of presentations including ID, ASD, and seizures
even within the same family. CC2D1A encodes a multifunctional
signaling scaffold that regulates multiple pathways involved in
neuronal differentiation by linking transmembrane receptors
and their downstream effectors, including protein kinase B
(PKB/AKT) activators (Nakamura et al., 2008), andmultiple effec-
tors upstream of activation of the transcription factor nuclear
factor kB (NF-kB) (Chang et al., 2011; Zhao et al., 2010).
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We performed both gain- and loss-of-function experiments to
define the role of Cc2d1a in neuronal differentiation and intracel-
lular trafficking. Cc2d1a depletion in murine neurons leads to a
striking reduction in dendritic complexity and dendritic spine
number. By exploring the involvement of Cc2d1a in a variety of
signaling pathways, we discovered that the NF-kB pathway
was most strongly affected. Cc2d1a loss and gain of function
both activated NF-kB in developing neurons, and restoring NF-
kB activity during differentiation rescued dendritic complexity
in Cc2d1a knockdown neurons. Our results suggest an impor-
tant role of Cc2d1a in regulating NF-kB activity during brain
development and that NF-kB activation may underlie some of
the defects caused by Cc2d1a loss of function.
Figure 1. CC2D1A Null Mutations Cause
Severe ID, ASD, and Seizures
(A) Four families with 16 individuals affected with
ID and ASD plus seizures. Affected individuals are
represented by shaded symbols (squares indicate
males; circles indicate females). Fam, family.
(B) All individuals in families 1, 2, and 3 carried a
splicing mutation at the junction of exon and intron
6 of CC2D1A (see gene schematic). Individuals in
family 4 carried a 1 bp deletion in exon 3 leading to
a frameshift in the coding sequence.
(C) The splicing mutation causes complete skip-
ping of exon 6 as shown by RT-PCR analysis of
cDNA from patient cell lines. NA, not affected; aff,
affected.
(D) The protein change p.T172Vfs*51 is predicted
to generate a 223 amino acid truncated protein
that could not be found by western blot in cell lines
from an affected individual, a parent (NA het), and
a normal control (NA).
(E) Schematic representation of the predicted
protein fragments generated by the identified
mutations. In all cases, mutations are predicted to
generate a complete loss-of-function phenotype.
RESULTS AND DISCUSSION
Null Mutations in CC2D1A Cause
ASD, ID, and Seizures
We report 4 families with a total of 16 indi-
viduals affected by a spectrum of cogni-
tive and social impairments, including
ASD, nonsyndromic ID (NSID), and sei-
zures (Figure 1A). Families 1 and 2 repre-
sent two related consanguineous families
from Saudi Arabia. In family 1, one male is
affected by ASD and ID (individual 1:4),
one male by cognitive problems and
aggressive behavior (1:1), and two fe-
males by moderate-to-severe NSID (1:2
and 1:3). In family 2, two males (2:1 and
2:2) and one female (2:3) are affected by
combinations of ASD, severe NSID, lan-
guage impairment, and seizures (Table
S1 for clinical information). The parents
in family 3 are first cousins once removed,
also from Saudi Arabia, and four siblings (three males and one
female) are affected by severe NSID with language impairment
(Table S1). Finally, five Pakistani males with variable presentation
belonged to family 4: individuals 4:1, 4:2, and 4:4 had moderate
NSID, individual 4:3 was more severely affected with language
impairment and borderline autistic features, and individual 4:5
had moderate ASD/ID (Table S1). The parents reported being
unrelated.
Genomic DNA from all family members was run on genome-
wide SNP arrays, and genotyping data were analyzed under an
autosomal recessive model. Linkage analysis was performed
independently on the first three families, but all studies identified
a common region on chromosome 19p13with a LODscore of 3.4
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Figure 2. Cc2d1a Knockdown Reduces Dendritic Complexity in Hippocampal Neurons
(A) Expression levels of Cc2d1a increase during early neuronal development in the mouse brain. qPCR analysis was performed in different tissues (cortex and
hippocampus) at the ages indicated. Mean and SEM were calculated from three independent samples per time point.
(legend continued on next page)
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for families 1 and 2 and of 3.8 for family 3. The locus had been
previously linked to NSID in Israeli-Arab families, who carried a
3,589 bp deletion in CC2D1A generating an 85 kDa protein frag-
ment (Basel-Vanagaite et al., 2006) making CC2D1A a strong
positional candidate gene. The Saudi families did not carry the
Israeli-Arab deletion (data not shown), but upon Sanger
sequencing of CC2D1A, we identified a homozygous G > T
transversion at the exon-intron junction of exon 6 (c.748+1 G >
T), which segregated with the disease in the families (Figure 1B).
The shared SNP haplotype observed in all affected individuals
indicated that c.748+1 G > T is a founder mutation in the Saudi
population shared by all three families and inherited from a
distant common ancestor (Figure S1). A common region of
homozygosity including CC2D1A was also identified in all
affected individuals in family 4. Exome sequencing identified a
1 bp deletion in exon 3 (c.346 delA) leading to an early frameshift
(p.Lys116Argfs*81) (Figure 1B). To determine whether additional
mutations in a different gene could be present in families 1, 2,
and 4 to explain the ASD phenotype, we reanalyzed the SNP
genotyping to ascertain whether a second region with identical
homozygous genotype was shared among the individuals with
ASD, but no such region was present.
WhenCC2D1AmRNA derived from patient lymphoblasts from
family 1 was analyzed via RT-PCR, it showed complete exclu-
sion of exon 6 (Figure 1C). This skipping of exon 6 leads to a
predicted frameshift at position 172 in the protein and an early
stop codon at position 223 (p. Thr172Valfs*51). Western blot
analysis of patient cell lines showed reduced CC2D1A expres-
sion in a heterozygous carrier and complete absence of
CC2D1A in the patient, either in the full-length or truncated
form (p.Thr172Valfs*51), showing that this mutation is null (Fig-
ure 1D). The frameshift mutation found in family 4 is predicted
to lead to an N-terminal fragment and not to preserve any known
domain, also leading to a complete loss of function (Figure 1E),
indicating that the ASD/ID presentations in the patients reflect
null mutations in CC2D1A.
Our findings show that CC2D1A loss of function causes an
unexpectedly wide range of cognitive and social phenotypes,
as well as seizures, in humans. Autosomal recessive mutations
have been recently estimated to account for at least 3% of
ASD cases (Lim et al., 2013), but many of these genes still remain
unidentified. Although in many instances ASD caused by such
recessive mutations represents a hypomorphic phenotype of a
known syndrome (Yu et al., 2013), CC2D1A stands out as the
only autosomal gene known to date whose complete loss of
function of both alleles leads to ASD with no other syndromic
presentations in males and females.
Loss of Cc2d1a Reduces Dendritic Complexity and
Synapse Number in Neurons
Cc2d1a has been shown to be expressed throughout the brain
(Basel-Vanagaite et al., 2006), andwe asked whether expression
is dynamic during development. Using quantitative PCR (qPCR),
we determined that Cc2d1amRNA expression in the developing
murine cortex and hippocampus shows an increase during the
postnatal period corresponding to early stages of postmitotic
neuronal differentiation, between embryonic day 18.5 (E18.5)
and postnatal day 1 (P1) in the cortex and hippocampus (Fig-
ure 2A), suggesting possible roles in neuronal morphogenesis
or synapse formation.
Cc2d1a knockout mouse studies have only provided limited
information on the role of this gene because both mouse lines
developed so far lead to lethality immediately after birth despite
the lack of gross abnormalities (Al-Tawashi et al., 2012; Zhao
et al., 2011). Analysis of primary neurons obtained from these
lines has yielded either a reduction (Al-Tawashi et al., 2012)
or no change in the dendritic arbor and defects in synaptic
maturation (Zhao et al., 2011). These findings suggest that
compensatory mechanisms may be in place leading to pheno-
typic variability as observed in the patients. We used an RNAi
approach to remove Cc2d1a during the perinatal period of
increasing expression and study its effect on neuronal develop-
ment. Multiple small hairpin RNA (shRNA) constructs targeted to
different sites on the Cc2d1amRNA reduced protein expression
more than 85% (Figure S2A). An untargetable shRNA was de-
signed by inserting five point mutations into one of the most
effective shRNAs to control for possible nonspecific effects of
the RNAi approach. All constructs included a GFP reporter to
identify transfected cells and outline neuronal morphology.
We first knocked down Cc2d1a in neuronal progenitors of the
developing mouse cortex via in utero electroporation of experi-
mental and control plasmids at E15.5 when Cc2d1a expression
begins to increase. Electroporated cells were analyzed at E18.5
and P11. At E18.5, Cc2d1a knockdown did not affect migration
or leading process extension or orientation because cortices
looked undistinguishable from control (Figure S2B). At P11, elec-
troporated neurons were found in the correct location in layer 2/
3, but their dendrites appeared abnormal: dendrites were
jumbled and misoriented, and the overall dendritic arbor was
smaller than in control conditions (Figure 2B). Dendritic arbor
length measurements in isolated cells showed a reduction in
the total dendritic length following Cc2d1a knockdown (Fig-
ure 2C; vector, 721.20 ± 45.84 mm; shRNA 1A, 477.61 ±
51.15 mm; shRNA 1Am, 747.90 ± 101.06 mm; p = 0.05). In addi-
tion, the apical dendrites were bent and did not extend toward
(B) A simplified dendritic arbor was observed in cortical neurons at P11 following in utero electroporation of shRNA constructs at E15.5. Dendrites also appeared
to be misoriented, terminating farther from the pial surface (red arrows). Scale bar, 50 mm.
(C) Total dendritic length was reduced by approximately 40% (three electroporated animals).
(D) Quantification of the disruption in dendrite orientation shown in (B). Although the nucleus was at the same distance from the pia, the apical dendritic arbor
ended much farther from the surface.
(E and F) Hippocampal neurons at 7 and 14 DIV following Cc2d1a knockdown at 1 DIV also showed a reduction in total dendritic length caused by a reduction in
process number. Average process length was not affected (n > 3 independent cultures). Scale bars, 50 mm (7 DIV) and 100 mm (14 DIV).
(G) The number of dendritic spines in hippocampal neurons (tested at 14 DIV) was reduced.
(H) The type of spine (mature, spine with a neck and head; stubby, spine with no neck; filopodia, elongated filamentous protrusion) was not changed in the
experimental group, suggesting that spine maturation was not affected (n = 6 for G and H).
All graphs show mean ± SEM. *p < 0.5; **p < 0.01; ***p < 0.001.
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the pial surface as in control cells terminating in the middle of the
molecular layer (Figure 2D).
To better quantify this phenotype, Cc2d1a was knocked down
in vitro in hippocampal cultures. shRNA plasmids were trans-
fected into primary hippocampal neurons 18 hr after plating.
Results from only one shRNA will be shown for simplicity, but
multiple shRNAs produced identical results (Figure S2C). In
neurons deficient in Cc2d1a, we observed abnormal neuronal
morphology starting 4–5 days after plating, and by 7 days
in vitro (DIV), there was a 50%–60% reduction in the number of
dendritic processes (dendrite number, 43.7% ± 6.9% of control;
p = 0.007; n = 3) and in the total dendritic arbor length (total
dendrite length, 52.6% ± 14.9% of control; p = 0.02; n = 3) (Fig-
ures 2E and 2F). Reduced dendritic complexity was also evident
at 14 DIV following Cc2d1a knockdown (dendrite number,
52.7% ± 4.9% of control, p = 0.03; total dendrite length,
56.6% ± 9.0% of control, p = 0.004, n = 4; Figures 2E and 2F),
and dendritic spine density was significantly reduced (spine
number per unit length, 42.4% ± 8.6% of control, p < 0.001,
n = 6; Figure 2G). To determine whether there were differences
in spine maturation or spine type, we counted the number of
spines with a head and a neck (mature), without a neck (stubby)
or filopodia, and found no differences in experimental or control
conditions (Figure 2H).
We then analyzed both excitatory and inhibitory synapse
density by determining colocalization of the AMPA receptor
subunit 1 (GluA1) and the synaptic vesicle marker synapsin I,
or the inhibitory synaptic scaffold gephyrin and the vesicular
g-aminobutyric acid (GABA) transporter (VGAT), respectively.
No change in synaptic density (number of puncta per 10 mm
of dendrite length) was observed in either excitatory or inhibi-
Figure 3. Cc2d1a Overexpression Preferen-
tially Activates NF-kB Signaling
(A) NF-kB shows the highest activation among 45
pathways assayed using luciferase reporter ar-
rays. Pathways showing significant activation are
presented here, and remaining pathways are given
in Figure S3 (n = 3).
(B) NF-kB activation is specific to Cc2d1a because
expression of the homolog Cc2d1b does not
activate NF-kB (n = 3). RLUs, relative lumines-
cence units.
(C) Cc2d1a knockdown only elicits a response in
NF-kB signaling at 7 DIV, but not at 2 DIV (n = 6).
(D) TNF-a treatment has different effects on
neurons following Cc2d1a knockdown or over-
expression. Cc2d1a knockdown prevents any
further activation of NF-kB transcriptional activity,
whereas treatment during overexpression causes
enhanced NF-kB activation (n = 4).
All graphs show mean ± SEM. *p < 0.5; **p < 0.01.
tory contacts (Figures.S2D and S2E),
indicating that loss of Cc2d1a may not
affect synapse formation rate directly.
Because synaptic density is maintained,
the reduced dendritic arbor length would
lead to a 50%–60% reduction in the total
number of excitatory and inhibitory syn-
apses for each neuron. These linked effects of Cc2d1a knock-
down on dendritic arbor complexity, synaptic spine number,
and synapse number show crucial roles in neuronal morpho-
genesis and circuit formation.
NF-kB Signaling Is Primarily Affected by Cc2d1a Gain
of Function
CC2D1A has been independently involved in multiple signaling
pathways, including AKT (Nakamura et al., 2008), NF-kB (Chang
et al., 2011; Zhao et al., 2010), RIG-I-like receptors (RLRs) (Chen
et al., 2012), and protein kinase A (PKA) (Al-Tawashi et al., 2012).
To determine the level of CC2D1A-mediated activation across
different pathways and whether other pathways are regulated
by CC2D1A, we employed a commercial array of 45 different
luciferase reporters assaying a range of signaling pathways,
including all known targets of CC2D1A (NF-kB, MAPK, CREB,
and AKT) and many other promoters that had not been tested
before (Figure S3A). Of all the promoters tested, Cc2d1a overex-
pression caused significant activation of NF-kB, activation
transcription factors 2, 3, and 4 (ATF2/ATF3/ATF4), interferon
response factor 1 (IRF1), Elk1/serum response factor (SRF),
and nuclear respiration factors 1 and 2 (Nrf1/Nrf2) (Figure 3A).
NF-kB showed by far the strongest response with 25.2- ± 7.9-
fold increase compared to cells transfected with empty vector
(p = 0.038). This was almost five times the activation of the
closest reporter ATF2/ATF3/ATF4, which was activated 5.5- ±
0.8-fold (p = 0.005). IRF1, which responds to interferon, antiviral
immunity downstream of RLRs (Dixit et al., 2010), and also
shows close interactions with the NF-kB pathway, was elevated
3.6 ± 0.7 times (p = 0.025). All reporters activated have been
involved in signaling crosstalk with NF-kB (Hoffmann and
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Baltimore, 2006), but it cannot be excluded that Cc2d1a is
important for regulation of additional signaling pathways. Even
within immune pathways upstream of NF-kB and interferon
response activation, Cc2d1a appears to be quite promiscuous
(Zhao et al., 2010), suggesting an important multifunctional
nature.
We focused on NF-kB as a preferred target because its activa-
tion by Cc2d1a was disproportionately higher than other path-
ways, and NF-kB has been involved in the regulation of neuronal
differentiation and survival (Mattson andMeffert, 2006). CC2D1A
has been shown to act as a scaffold, coupling NF-kB activation
with Toll-like receptor signaling in the endosome (Chang et al.,
2011) and to control NF-kB via the canonical pathway (Zhao
et al., 2010). The Cc2d1a homolog, Cc2d1b, has similar topology
and structure (Figure S3B) and has been shown to share interac-
tors with Cc2d1a (Martinelli et al., 2012; Usami et al., 2012), sug-
gesting that these proteinsmay be redundant. However, Cc2d1b
overexpression did not elicit an increase in NF-kBactivation (Fig-
ure 3B), indicating that NF-kB activation is specific to Cc2d1a.
NF-kB Modulation Restores Dendritic Complexity
following Cc2d1a Loss of Function
NF-kB is an important regulator of neurite outgrowth down-
stream of brain-derived neurotrophic factor (BDNF) and in con-
cert with Notch (Bonini et al., 2011; Salama-Cohen et al.,
2005), and NF-kB activation can increase or decrease dendritic
complexity in ways that are pathway and context dependent
(Gavalda` et al., 2009; Gutierrez et al., 2008). Therefore, we asked
whether the dendritic phenotype observed following Cc2d1a
loss of function in developing neurons could reflect dysregula-
tion of NF-kB transcriptional activity. We tested NF-kB activity
changes by cotransfecting luciferase reporter constructs in par-
allel with Cc2d1a knockdown. No change in NF-kB activity was
observed following CC2D1A knockdown in human embryonic
kidney 293 (HEK293) cells (Figures S4A and S4B), whereas
Cc2d1a knockdown during hippocampal neuron differentiation
had differential effects on NF-kB function. Early during differen-
tiation at 2 DIV, we found no effect of Cc2d1a depletion onNF-kB
activity, but NF-kB activation was moderately and significantly
increased above control conditions during the peak of dendrite
extension at 7 DIV in Cc2d1a knockdown neurons (luciferase ac-
tivity, 1.78 ± 0.22 of control; n = 5; p = 0.014; Figure 3C). These
data suggest that the regulation of NF-kB via Cc2d1amay vary in
different contexts and that neurons may be more sensitive to
Cc2d1a loss of function. Because our data are normalized to
control conditions at 2 and 7 DIV, the known developmental in-
crease in NF-kB activity during normal neuronal differentiation
may not be immediately apparent (Boersma et al., 2011). In
fact, NF-kB activity varies dynamically during development,
and we speculate that the further increase in NF-kB-mediated
transcription following Cc2d1a knockdown could reflect the
dysregulation of this mechanism. The fly ortholog of Cc2d1a,
lgd, displayed similar effects in gain- and loss-of-function exper-
iments, where both manipulations led to increases in Notch
signaling (Jaekel and Klein, 2006). In the mouse brain, Cc2d1a
may similarly regulate a finely balanced NF-kB signaling
mechanism, which is disrupted both by overexpression and
knockdown.
To define whether the NF-kB activation following Cc2d1a
overexpression and knockdown was mediated via the same
mechanisms, we also challenged the neurons with tumor necro-
sis factor a (TNF-a). Treatment with 100 ng/ml of TNF-a elicited
different responses in neurons following Cc2d1a overexpression
and knockdown leading to a substantial increase in NF-kB acti-
vation following overexpression and to no effect upon knock-
down (Figure 3D). The knockdown result is in concordance
with studies in cell lines showing that removal of Cc2d1a pre-
vents the cell from responding to stimuli (Chang et al., 2011;
Zhao et al., 2010), whereas the increase following overexpres-
sion suggests that different mechanismsmay be at play whereby
stimulation is amplified by increased Cc2d1a expression.
Cc2d1a overexpression has been shown to be involved in regu-
lating NF-kB activation via the canonical activation pathway
(Zhao et al., 2010), and it is possible that in the absence of
Cc2d1a, noncanonical NF-kB activation can be triggered either
because Cc2d1a is normally sequestering and trafficking spe-
cific effector proteins or tethering effectors to the canonical
branch of the pathway.
To test whether increased NF-kB activation could be respon-
sible for the dendritic phenotype observed in neurons following
Cc2d1a knockdown, we reduced NF-kB activity using two com-
pounds targeting NF-kB nuclear translocation: SN50, a peptide
inhibitor, and JSH-23, a small molecule inhibitor. Although
SN50 has been widely used to modulate NF-kB activity, JSH-
23, which has been shown to be very effective in reducing NF-
kBactivation following lipopolysaccharide treatment, is relatively
untested (Shin et al., 2004). Therefore, before treating neuronal
cultures with JSH-23, we tested its effectiveness in HEK293 cells
and determined that it was able to block NF-kB activation
following a variety of stimuli, such as TNF-a and Cc2d1a overex-
pression (Figure S4C). Because constitutive NF-kB activity in-
creases during differentiation and is necessary for neuronal
survival (Bhakar et al., 2002), blocking NF-kB with maximal con-
centrations of SN50 (20 mM) led to cell death within 12 hr (data
not shown). In an attempt to only partially reduce NF-kB activity
without completely blocking it, we lowered the concentration of
both drugs below the half-maximal effective concentration
(EC50) to try and restore normal signaling levels. We treated hip-
pocampal neurons with 5 mM of SN50 and the inactive peptide
SN50m or 5 mM of JSH-23 every 1.5 days from 4 DIV, when
the dendritic phenotype first becomes evident, to 7 DIV. We
found that treatment with SN50 and JSH-23, but not the inactive
control peptide SN50m, rescued dendritic complexity inCc2d1a
RNAi-treated cells (Figures 4A and 4B; SN50 treatment: vector,
92.1% ± 5.5% of untreated control, and shRNA 1A, 81.9% ±
6.0% of untreated control, p = 0.26, n = 4; SN50m treatment:
vector, 104.6% ± 7.8% of untreated control, and shRNA 1A,
66.8% ± 2.8% of untreated control, p = 0.004, n = 4; JSH-23
treatment: vector, 99.7% ± 9.1% of untreated control, and
shRNA 1A, 77.4% ± 7.1%, p = 0.21, n = 4), indicating that
loss of Cc2d1a impairs dendritic initiation via an NF-kB-depen-
dent mechanism. NF-kB signaling is finely controlled in neu-
rons, presumably because it is responsible for controlling
morphogenesis, synapse formation, and plasticity but can
also trigger cell death (Mattson and Meffert, 2006), and our re-
sults show that Cc2d1a levels must be also tightly regulated.
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Because of the essential role of NF-kB in neuronal survival, it is
unclear whether the reduction in dendritic complexity following
Cc2d1a knockdown is a reflection of reduced neuronal
health or whether it is a specific effect of NF-kB on dendrite
formation.
CC2D1A’s cellular role appears to be very complex. It has
been studied independently in endosomal trafficking in the fruit
fly (Gallagher and Knoblich, 2006; Troost et al., 2012), membrane
scission in HIV budding (Martinelli et al., 2012; Usami et al.,
2012), intracellular signaling in mouse and human cells (Chen
et al., 2012; Nakamura et al., 2009; Zhao et al., 2010), and tran-
scriptional control of serotonin receptors (Ou et al., 2003), and it
is still not known how these functions relate to each other.
Because the Cc2d1 proteins have a unique structure and are
the only genes in the genome with DM14 protein-binding do-
mains, they may have a dedicated role in integrating different
pathways, and Cc2d1a may be the only family member involved
in NF-kB regulation.
The effects of CC2D1A on NF-kB function provide an
intriguing potential explanation for the phenotypes of patients
that share identical homozygous null mutations in CC2D1A
because in different patients, loss of CC2D1A might manifest
slightly differently, leading to distinct phenotypes. Although
complete loss of NF-kB function is lethal in the mouse, deficits
in regulating NF-kB signaling disrupt learning and memory in
multiple mouse models (Meffert et al., 2003; O’Mahony et al.,
2006; O’Riordan et al., 2006), and mutations in TRAPPC9, a
binding protein for both NF-kB-inducing kinase and the IkB ki-
nase, have been described in families with ID (Mir et al., 2009;
Figure 4. Treatment with NF-kB Inhibitors
Rescues Dendritic Complexity following
Cc2d1a Knockdown
(A) In independent experiments, hippocampal
neurons were treated with NF-kB inhibitor JSH-23
(top panels) or NF-kB inhibitor SN50 and the
inactive control peptide SN50m (bottom panels).
Scale bar, 50 mm.
(B) Dendrite number quantification shows that
both inhibitors restore dendritic complexity in
hippocampal cultures (n = 4 for each inhibitor). All
graphs showmean ±SEM. **p < 0.01; ***p < 0.001;
n.s., not significant.
Mochida et al., 2009; Philippe et al.,
2009). Our findings on CC2D1A and find-
ings on TRAPPC9 indicate that the NF-
kB pathway deserves much stronger
scrutiny in human genetic studies and
that NF-kB signaling is a possible thera-
peutic target for cognitive disorders.
EXPERIMENTAL PROCEDURES
Patient Enrollment and Clinical Studies
This study was approved by the institutional
review boards of Boston Children’s Hospital and
of King Faisal Specialist Hospital and Research
Center. All affected individuals were examined
by a neurologist or a medical geneticist (M.A.S.,
M.G., Z.A.N., R.S., or F.S.A.) and received a comprehensive health
assessment.
Linkage Analysis and DNA Sequencing
Linkage analysis using genotyping of genomic DNA using SNP arrays ormicro-
satellites and sequencing of CC2D1A (NM_017721)-coding region was per-
formed using standard methods as detailed in the Supplemental Experimental
Procedures.
Patient Cell Lines and Mutated Protein Detection
Transformed lymphoblastoid cell lines were established from the peripheral
blood of affected and unaffected individuals at the Partners Center for Person-
alized Genetic Medicine (Cambridge). Cell line maintenance, lysate prepara-
tion, and western blotting are detailed in the Supplemental Experimental
Procedures. The presence of CC2D1A was assessed using a mouse poly-
clonal antibody raised against the full-length human CC2D1A protein (Abcam).
qPCR
All animal care and use were in accordance with institutional guidance
and approved by the Institutional Animal Care and Use Committee of Boston
Children’s Hospital. cDNA samples frommouse brain tissue were dissected at
the times indicated from NIH Swiss dams. mRNA was extracted using ReliaP-
rep RNAMiniprep System (Promega), and cDNAwas synthesized using iScript
Reverse Transcription Supermix (Bio-Rad). qPCR was performed using SYBR
green reagents (SsoFast EvaGreen Supermix fromBio-Rad) on a Bio-Rad plat-
form (CFX384). Expression was normalized to b-actin (Actb); relative expres-
sion levels are indicated as ratio to the cDNA from the earliest time available.
In Utero Electroporation
In utero electroporations were performed as previously described by Olson
et al. (2006). shRNA description and validation are available in the Supple-
mental Experimental Procedures. As many as ten embryos were electropo-
rated per dam and were then allowed to develop after surgery for defined
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periods. Pups were transcardially perfused, and brains were then sectioned to
150–300 mm sections on a vibratome (Leica), and sections were immuno-
stained for GFP to visualize electroporated cells. 3D reconstruction of electro-
porated neurons was performed by generating z stacks on a Zeiss LSM510
confocal microscope. Dendrite length was measured on 3D reconstructed
cells using the Filament function of Imaris software (Bitplane).
Neuronal Cell Culture and Analysis
Hippocampal cultures were prepared as described in the Supplemental
Experimental Procedures, fixed with 4% paraformaldehyde at the time points
indicated, and transfected neurons were immunostained for GFP to reveal
dendrite morphology. A detailed description of dendritic and synaptic analysis
is available in the Supplemental Experimental Procedures. Briefly, dendrite
length and number and spine number were measured for at least ten cells
per condition. Spine number was normalized by dendrite length to determine
density. For synaptic density analysis, cells were stained for excitatory (GluA1,
synapsin I) or inhibitory (gephyrin, VGAT) markers, and puncta colocalization
was quantified on GFP-positive dendrites.
45-Pathway Array and Luciferase Assays
N-terminal HA-tagged Cc2d1a was generated by cloning full-length Cc2d1a in
frame into pCMV-HA vector from Clontech Laboratories. Cignal Finder 45-
Pathway Reporter arrays (SABiosciences) were transfected with HA-Cc2d1a
or control vector following the protocol from the manufacturer, and firefly
and Renilla luciferase activity was assayed 24 hr after transfection using
Dual-Luciferase Reporter Assay System (Promega) in a Victor2 plate reader
(PerkinElmer). Follow-up experiments testing NF-kB activity in HEK293 cells
and neuronal cultures were performed as described in the Supplemental
Experimental Procedures.
SN50 and JSH-23 Treatments
Primary hippocampal neuronal cultures were transfected using shRNA or
control vectors as in previous experiments. At 4 DIV, cells were treated with
5 mM of SN50, SN50m (both from Calbiochem), or JSH-23 (Sigma-Aldrich)
or fresh medium. Treatments to replenish fresh drugs were repeated after
1.5 days by a complete medium change, and cells were fixed at 7 DIV using
4% paraformaldehyde. Dendrite analysis was performed as described above.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.06.039.
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